Platinum alkylating agents-based chemotherapy is the first-line chemotherapy for ovarian cancer, so we used cisplatin (platinum chemotherapy drugs) as an inducer to detect the effect of SLC11A2 knockdown on ovarian cancer cells. The gene discussed is SLC11A2; the disease is ovarian cancer.